Profile
From: WHO, 2015. Kenya Malaria Profile. Geneva: World Health Organization. Available at: www.who.int
Epidemiological profile of Kenya
| Population by malaria endemicity (000) | 2015 | % |
|---|---|---|
| High transmission (≥ 1 case per 1000 population) | 32 300 | 70 |
| Low transmission (0-1 cases per 1000 population) | 13 700 | 30 |
| Malaria free (0 cases) | 0 | - |
| Total | 46 050 |
| Parasites and vectors | |
|---|---|
| Major plasmodium species | P. falciparum (100%), P. vivax (0%) |
| Major anopheles species | An. gambiae, arabiensis, funestus, merus |
Intervention policies and strategies
| Intervention | WHO-recommended policy/strategy | Yes/no | Year adopted |
|---|---|---|---|
| ITN/LLIN |
ITNs/LLINs distributed free of charge ITNs/LLINs distributed to all age groups |
Yes Yes |
2006 2010 |
| IRS |
IRS is recommended DDT is used for IRS |
Yes No |
2003 - |
| IPT | IPT is used to prevent malaria during pregnancy | Yes | 2001 |
| Case management |
Patients of all ages should receive diagnostic test RDTs used at community level ACT is free for all ages in public sector Pre-referral treatment with recommended medicines Marketing authorization for all oral artemisinin-based monotherapies withdrawn |
Yes No Yes Yes No |
2009 -- 2006 2006 -- |
| Antimalarial policy | Type of medicine | Year adopted |
|---|---|---|
| First-line treatment of unconfirmed malaria | AL | 2004 |
| First-line treatment of P.falciparum | AL | 2004 |
| For treatment failure of P.falciparum | QN | 2004 |
| Treatment of severe malaria | AS; AM; QN | 2004 |
| Treatment of P.vivax | - | - |
Therapeutic efficacity tests (therapeutic or parasitological failure, %)
| Medicine | Year | No. of studies | Min. | Median | Max. | Follow-up |
| AL | 2005-2014 | 17 | 0 | 1.9 | 6.6 | 28 days |
